By combining Nivolumab with CAF-targeting agents, such as TGF-β inhibitors or FAP inhibitors, the therapy can simultaneously reduce the immunosuppressive effects of CAFs and enhance the immune response against tumor cells (114). The gene discussed is TGFB1; the disease is neoplasm.